Literature DB >> 22766072

C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect.

Antonia Ratti1, Lucia Corrado, Barbara Castellotti, Roberto Del Bo, Isabella Fogh, Cristina Cereda, Cinzia Tiloca, Carla D'Ascenzo, Alessandra Bagarotti, Viviana Pensato, Michela Ranieri, Stella Gagliardi, Daniela Calini, Letizia Mazzini, Franco Taroni, Stefania Corti, Mauro Ceroni, Gaia D Oggioni, Kuang Lin, John F Powell, Gianni Sorarù, Nicola Ticozzi, Giacomo P Comi, Sandra D'Alfonso, Cinzia Gellera, Vincenzo Silani.   

Abstract

A hexanucleotide repeat expansion (RE) in C9ORF72 gene was recently reported as the main cause of amyotrophic lateral sclerosis (ALS) and cases with frontotemporal dementia. We screened C9ORF72 in a large cohort of 259 familial ALS, 1275 sporadic ALS, and 862 control individuals of Italian descent. We found RE in 23.9% familial ALS, 5.1% sporadic ALS, and 0.2% controls. Two cases carried the RE together with mutations in other ALS-associated genes. The phenotype of RE carriers was characterized by bulbar-onset, shorter survival, and association with cognitive and behavioral impairment. Extrapyramidal and cerebellar signs were also observed in few patients. Genotype data revealed that 95% of RE carriers shared a restricted 10-single nucleotide polymorphism haplotype within the previously reported 20-single nucleotide polymorphism risk haplotype, detectable in only 27% of nonexpanded ALS cases and in 28% of controls, suggesting a common founder with cohorts of North European ancestry. Although C9ORF72 RE segregates with disease, the identification of RE both in controls and in patients carrying additional pathogenic mutations suggests that penetrance and phenotypic expression of C9ORF72 RE may depend on additional genetic risk factors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22766072     DOI: 10.1016/j.neurobiolaging.2012.06.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  27 in total

1.  Jump from pre-mutation to pathologic expansion in C9orf72.

Authors:  Zhengrui Xi; Marka van Blitterswijk; Ming Zhang; Philip McGoldrick; Jesse R McLean; Yana Yunusova; Erin Knock; Danielle Moreno; Christine Sato; Paul M McKeever; Raphael Schneider; Julia Keith; Nicolae Petrescu; Paul Fraser; Maria Carmela Tartaglia; Matthew C Baker; Neill R Graff-Radford; Kevin B Boylan; Dennis W Dickson; Ian R Mackenzie; Rosa Rademakers; Janice Robertson; Lorne Zinman; Ekaterina Rogaeva
Journal:  Am J Hum Genet       Date:  2015-05-21       Impact factor: 11.025

Review 2.  The Genetics of C9orf72 Expansions.

Authors:  Ilse Gijselinck; Marc Cruts; Christine Van Broeckhoven
Journal:  Cold Spring Harb Perspect Med       Date:  2018-04-02       Impact factor: 6.915

Review 3.  How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?

Authors:  Marka van Blitterswijk; Mariely DeJesus-Hernandez; Rosa Rademakers
Journal:  Curr Opin Neurol       Date:  2012-12       Impact factor: 5.710

4.  Validation of a Long-Read PCR Assay for Sensitive Detection and Sizing of C9orf72 Hexanucleotide Repeat Expansions.

Authors:  EunRan Suh; Kaitlyn Grando; Vivianna M Van Deerlin
Journal:  J Mol Diagn       Date:  2018-08-20       Impact factor: 5.568

5.  Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population.

Authors:  Mfon E Umoh; Christina Fournier; Yingjie Li; Meraida Polak; Latoya Shaw; John E Landers; William Hu; Marla Gearing; Jonathan D Glass
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

Review 6.  Frontotemporal dementia: a bridge between dementia and neuromuscular disease.

Authors:  Adeline S L Ng; Rosa Rademakers; Bruce L Miller
Journal:  Ann N Y Acad Sci       Date:  2014-12-30       Impact factor: 5.691

7.  Absence of C9ORF72 expanded or intermediate repeats in autopsy-confirmed Parkinson's disease.

Authors:  Karen Nuytemans; Vanessa Inchausti; Gary W Beecham; Liyong Wang; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Deborah C Mash; Matthew P Frosch; Tatiana M Foroud; Lawrence S Honig; Thomas J Montine; Ted M Dawson; Eden R Martin; William K Scott; Jeffery M Vance
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

8.  Regulation of FMO and PON detoxication systems in ALS human tissues.

Authors:  Stella Gagliardi; Kenneth Abel; Marika Bianchi; Pamela Milani; Stefano Bernuzzi; Manuel Corato; Mauro Ceroni; John R Cashman; Cristina Cereda
Journal:  Neurotox Res       Date:  2012-10-17       Impact factor: 3.911

Review 9.  Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.

Authors:  Maria Sara Cipolat Mis; Simona Brajkovic; Francesco Tafuri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2016-06-28       Impact factor: 5.590

10.  Searching for Grendel: origin and global spread of the C9ORF72 repeat expansion.

Authors:  Hannah A Pliner; David M Mann; Bryan J Traynor
Journal:  Acta Neuropathol       Date:  2014-02-05       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.